MediScan

Executive Summary

MediScan is a Swiss medtech company specializing in non-invasive, point-of-care diagnostic devices for early detection and monitoring of cancer and cardiovascular diseases. Leveraging AI-driven software and advanced imaging hardware, its solutions aim to democratize access to precise diagnostics for clinicians. Founded in 2017 and headquartered in Lausanne, the company has raised $185 million in funding, reflecting strong investor confidence. At the commercial stage with 200–500 employees, MediScan is poised to disrupt the traditional diagnostics market by reducing reliance on centralized labs and enabling real-time decision-making. The company’s dual focus on oncology and cardiology addresses two of the largest healthcare burdens globally, and its AI integration differentiates it from conventional imaging players. With a robust capital base and a clear go-to-market strategy, MediScan is well-positioned to expand its installed base and capture market share. However, regulatory hurdles and competition from established diagnostic conglomerates remain key risks.

Upcoming Catalysts (preview)

• Q3 2026CE Mark approval for next-generation multi-cancer screening platform70% success
• Q4 2026Strategic partnership with a top-10 European hospital network60% success
• H2 2026Series D funding round of $100M+ led by a prominent healthcare VC65% success